GRFSNasdaqPharmaceutical PreparationsAlso trades as GIFLF, GIFOF, GIKLY
Grifols SA
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 17, 2026
$7.64+0.00 (0.00%)
Close on Oct 19, 2026
Grifols statistics
Financials through Dec 31, 2024, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Income (trailing twelve months)
| Measure | Grifols | Industry median |
|---|---|---|
| Revenue | €7.21B | €447.40M |
| Gross Profit | €2.79B | €1.08B |
| Operating Income | €1.19B | -€68.03M |
| Pretax Income | €444.00M | -€49.18M |
| Net Income | €156.92M | -€6.53M |
| EBITDA | €1.63B | -€48.04M |
| EPS (Diluted) | 0.23 EUR | -0.61 EUR |
Margins
| Measure | Grifols | Industry median |
|---|---|---|
| Gross Margin | 38.7% | 42.8% |
| Operating Margin | 16.5% | -33.2% |
| Pretax Margin | 6.16% | -36.6% |
| Profit Margin | 2.18% | -31.7% |
| EBITDA Margin | 22.6% | -28.6% |
| FCF Margin | 9.28% | -24.4% |
Returns
| Measure | Grifols | Industry median |
|---|---|---|
| Return on Equity (ROE) | 2.67% | 2.67% |
| Return on Assets (ROA) | 0.73% | -5.10% |
| Return on Invested Capital (ROIC) | 7.88% | |
| Return on Capital Employed (ROCE) | 6.19% | -26.9% |
Growth
| Measure | Grifols | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 9.41% | 1.99% |
| Net Income Growth (YoY) | 270.8% | |
| EPS Growth (YoY) | 283.3% | 67.4% |
| Revenue Growth (3Y CAGR) | 13.5% | 13.5% |
| Revenue Growth (5Y CAGR) | 7.18% | 11.0% |
| EPS Growth (3Y CAGR) | -6.35% | |
| EPS Growth (5Y CAGR) | -24.0% |
Balance sheet
| Measure | Grifols | Industry median |
|---|---|---|
| Cash & Short-Term Investments | €979.78M | €291.68M |
| Total Debt | €2.66B | €496.91M |
| Net Cash (Debt) | -€1.68B | €87.54M |
| Net Cash Per Share | -2.44 EUR | 1.09 EUR |
| Equity (Book Value) | €5.88B | €952.53M |
| Book Value Per Share | 8.56 EUR | 5.36 EUR |
| Tangible Book Value | -€4.45B | €21.84M |
| Working Capital | €3.57B | €121.78M |
Financial position
| Measure | Grifols | Industry median |
|---|---|---|
| Current Ratio | 2.66 | 2.81 |
| Quick Ratio | 0.84 | 1.23 |
| Debt / Equity | 0.45 | |
| Debt / EBITDA | 1.63 | |
| Debt / FCF | 3.97 | |
| Net Debt / EBITDA | 1.03 | |
| Interest Coverage | 1.67 | -0.90 |
Cash flow (trailing twelve months)
| Measure | Grifols | Industry median |
|---|---|---|
| Operating Cash Flow | €902.17M | -€35.31M |
| Capital Expenditures | -€232.54M | -€4.42M |
| Free Cash Flow | €669.63M | -€53.81M |
| FCF Per Share | 0.97 EUR | -0.56 EUR |
Efficiency
| Measure | Grifols | Industry median |
|---|---|---|
| Asset Turnover | 0.34 | 0.32 |
| Inventory Turnover | 1.24 | 1.33 |
| Revenue Per Employee | €4.47M | €420.86K |
| Profits Per Employee | €97.28K | -€247.02K |
| Employee Count | 1,613 | 378 |
Dividends and yields
| Measure | Grifols | Industry median |
|---|---|---|
| Payout Ratio | 0.61% | |
| FCF Payout Ratio | 0.14% |
Shares
| Measure | Grifols | Industry median |
|---|---|---|
| Shares Outstanding | 687,555,000 | 105,361,000 |
| Shares Change (YoY) | 0.42% | 6.28% |
| Float | 687,555,000 | 78,574,400 |
| Shares Held by Insiders | 0.00% | 9.05% |
| Shares Held by Institutions | 20.8% | 13.8% |
Taxes
| Measure | Grifols | Industry median |
|---|---|---|
| Income Tax | €231.19M | €1.53M |
| Effective Tax Rate | 52.1% |
Scores
| Measure | Grifols | Industry median |
|---|---|---|
| Graham Number | 6.65 EUR | |
| Piotroski F-Score | 8 | 5 |
| Beneish M-Score | -2.43 |
Calculated by StockData from Grifols's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.